Overview

• Two peer-reviewed papers in the British Journal of Cancer evaluated data from more than 340,000 women across England.
• Ovatools combines CA125 blood-test results with a patient’s age to generate individualized risk scores for GP triage.
• Validation showed stronger accuracy in women over 50, identifying those who warrant urgent referral and specialist assessment.
• Economic modeling found use in patients 50 and older would detect more cancers earlier while staying within NICE affordability thresholds.
• Study authors and funders from Queen Mary University of London, NIHR and Cancer Research UK call for real-world implementation studies before routine NHS rollout.